A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial-Reference-Cited by-同舟云学术

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

Published:2021-02 Issue:10275 Volume:397 Page:695-703
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Pal Sumanta K,Tangen Catherine,Thompson Ian M,Balzer-Haas Naomi,George Daniel J,Heng Daniel Y C,Shuch Brian,Stein Mark,Tretiakova Maria,Humphrey Peter,Adeniran Adebowale,Narayan Vivek,Bjarnason Georg A,Vaishampayan Ulka,Alva Ajjai,Zhang Tian,Cole Scott,Plets Melissa,Wright John,Lara Primo N

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

General Medicine

Reference26 articles.

1. Systemic therapy for non-clear cell renal cell carcinoma;Zhang;Am Soc Clin Oncol Educ Book,2017

2. Comprehensive molecular characterization of papillary renal-cell carcinoma;Linehan;N Engl J Med,2016

3. The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours;Moch;Eur Urol,2016

4. Characterization of clinical cases of advanced papillary renal cell carcinoma via comprehensive genomic profiling;Pal;Eur Urol,2018

5. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array;Albiges;Clin Cancer Res,2014

Cited by 183 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma;Journal of Chemotherapy;2024-09-10

2. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma;Journal of Clinical Oncology;2024-09-10

3. Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan;International Journal of Clinical Oncology;2024-09-02

4. Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapy;Japanese Journal of Clinical Oncology;2024-08-23

5. Drug-induced liver injury associated with savolitinib: a novel case report and causality assessment;BMC Pulmonary Medicine;2024-08-09